Welcome to LookChem.com Sign In|Join Free
  • or
2-oxo(1-~14~C)propanoic acid is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

25713-22-8

Post Buying Request

25713-22-8 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

25713-22-8 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 25713-22-8 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 2,5,7,1 and 3 respectively; the second part has 2 digits, 2 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 25713-22:
(7*2)+(6*5)+(5*7)+(4*1)+(3*3)+(2*2)+(1*2)=98
98 % 10 = 8
So 25713-22-8 is a valid CAS Registry Number.

25713-22-8SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 15, 2017

Revision Date: Aug 15, 2017

1.Identification

1.1 GHS Product identifier

Product name [14C]-Pyruvic acid

1.2 Other means of identification

Product number -
Other names (14C) pyruvic acid

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:25713-22-8 SDS

25713-22-8Upstream product

25713-22-8Downstream Products

25713-22-8Relevant academic research and scientific papers

THERAPEUTICS FOR CANCER USING 3-BROMOPYRUVATE AND OTHER SELECTIVE INHIBITORS OF ATP PRODUCTION

-

Page/Page column 55, (2008/12/06)

The present invention relates to methods of treating a cancerous tumor in a subject comprising administering to the subject an effective amount of 3-bromopyruvate. The 3- bromopyruvate may be administered intraarterially directly to a tumor as a continous intraarterial infusion. The present invention also relates to methods for identifying agents that inhibit type II hexokinase activity.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 25713-22-8